• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

计算预测帕罗韦德与处方药之间的相互作用。

Computational prediction of interactions between Paxlovid and prescription drugs.

机构信息

Metabolic and Biomolecular Engineering National Research Laboratory, Department of Chemical and Biomolecular Engineering (BK21 four), Korea Advanced Institute of Science and Technology, Daejeon 34141, Republic of Korea.

Systems Metabolic Engineering and Systems Healthcare Cross-Generation Collaborative Laboratory, Korea Advanced Institute of Science and Technology, Daejeon 34141, Republic of Korea.

出版信息

Proc Natl Acad Sci U S A. 2023 Mar 21;120(12):e2221857120. doi: 10.1073/pnas.2221857120. Epub 2023 Mar 13.

DOI:10.1073/pnas.2221857120
PMID:36913586
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10041137/
Abstract

Pfizer's Paxlovid has recently been approved for the emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for the treatment of mild-to-moderate COVID-19. Drug interactions can be a serious medical problem for COVID-19 patients with underlying medical conditions, such as hypertension and diabetes, who have likely been taking other drugs. Here, we use deep learning to predict potential drug-drug interactions between Paxlovid components (nirmatrelvir and ritonavir) and 2,248 prescription drugs for treating various diseases.

摘要

辉瑞公司的帕克洛维德(Paxlovid)最近获得了美国食品和药物管理局(FDA)的紧急使用授权(EUA),用于治疗轻度至中度的 COVID-19。对于患有高血压和糖尿病等潜在疾病的 COVID-19 患者,药物相互作用可能是一个严重的医疗问题,因为他们可能已经在服用其他药物。在这里,我们使用深度学习来预测帕克洛维德(nirmatrelvir 和 ritonavir)成分与 2248 种治疗各种疾病的处方药之间潜在的药物相互作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d021/10041137/ce4469bd5507/pnas.2221857120fig02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d021/10041137/665d6b82be44/pnas.2221857120fig01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d021/10041137/ce4469bd5507/pnas.2221857120fig02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d021/10041137/665d6b82be44/pnas.2221857120fig01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d021/10041137/ce4469bd5507/pnas.2221857120fig02.jpg

相似文献

1
Computational prediction of interactions between Paxlovid and prescription drugs.计算预测帕罗韦德与处方药之间的相互作用。
Proc Natl Acad Sci U S A. 2023 Mar 21;120(12):e2221857120. doi: 10.1073/pnas.2221857120. Epub 2023 Mar 13.
2
Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment - California, December 2021-May 2022.加利福尼亚州 2021 年 12 月至 2022 年 5 月辉瑞公司新冠口服药 Paxlovid 治疗后因 COVID-19 住院和急诊就诊情况。
MMWR Morb Mortal Wkly Rep. 2022 Jun 24;71(25):830-833. doi: 10.15585/mmwr.mm7125e2.
3
Optimizing the use of Paxlovid in clinical practice.优化帕罗韦德在临床实践中的使用。
Drugs Today (Barc). 2022 Nov;58(11):539-546. doi: 10.1358/dot.2022.58.11.3461265.
4
Genetic Surveillance of SARS-CoV-2 M Reveals High Sequence and Structural Conservation Prior to the Introduction of Protease Inhibitor Paxlovid.SARS-CoV-2 M 基因监测显示,在引入蛋白酶抑制剂帕克洛维德之前,其序列和结构高度保守。
mBio. 2022 Aug 30;13(4):e0086922. doi: 10.1128/mbio.00869-22. Epub 2022 Jul 13.
5
Paxlovid for treatment of COVID-19.用于治疗新冠病毒病的帕罗韦德
Med Lett Drugs Ther. 2022 Jan 24;64(1642):9-10.
6
COVID-19 update: Prescription of Paxlovid by pharmacists.新冠疫情最新情况:药剂师开具帕罗韦德处方。
Med Lett Drugs Ther. 2022 Aug 8;64(1656):e124.
7
Exploring Paxlovid Efficacy in COVID-19 Patients with MAFLD: Insights from a Single-Center Prospective Cohort Study.探讨 MAFLD 患者应用 Paxlovid 的疗效:一项单中心前瞻性队列研究的启示。
Viruses. 2024 Jan 12;16(1):112. doi: 10.3390/v16010112.
8
A case report of severe hyponatremia secondary to Paxlovid-induced SIADH.一例因帕罗韦德诱发抗利尿激素分泌异常综合征导致严重低钠血症的病例报告。
Clin Case Rep. 2023 Aug 29;11(9):e7860. doi: 10.1002/ccr3.7860. eCollection 2023 Sep.
9
Public Health Impact of Paxlovid as Treatment for COVID-19, United States.辉瑞公司研发的新冠病毒治疗药物 Paxlovid 对公共卫生的影响,美国。
Emerg Infect Dis. 2024 Feb;30(2):262-269. doi: 10.3201/eid3002.230835. Epub 2024 Jan 5.
10
Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs.莫努匹韦和奈玛特韦-利托那韦:口服冠状病毒病 2019 抗病毒药物。
Clin Infect Dis. 2023 Jan 6;76(1):165-171. doi: 10.1093/cid/ciac180.

引用本文的文献

1
Frequency, type and severity of drug-related problems and pharmacist interventions in Paxlovid® prescribing: a descriptive analysis.帕罗韦德(Paxlovid®)处方中药物相关问题的频率、类型和严重程度以及药剂师的干预措施:一项描述性分析
Int J Clin Pharm. 2025 Apr;47(2):471-476. doi: 10.1007/s11096-024-01852-5. Epub 2024 Dec 21.

本文引用的文献

1
Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System : A Population-Based Cohort Study.尼马曲韦/利托那韦片在大型美国医疗体系中治疗早期 COVID-19:一项基于人群的队列研究。
Ann Intern Med. 2023 Jan;176(1):77-84. doi: 10.7326/M22-2141. Epub 2022 Dec 13.
2
Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge.奈玛特韦利特的使用与奥密克戎疫情期间的严重新冠结局。
N Engl J Med. 2022 Sep 1;387(9):790-798. doi: 10.1056/NEJMoa2204919. Epub 2022 Aug 24.
3
Drug Interactions for Patients with Respiratory Diseases Receiving COVID-19 Emerged Treatments.
接受新冠病毒治疗的呼吸疾病患者的药物相互作用。
Int J Environ Res Public Health. 2021 Nov 8;18(21):11711. doi: 10.3390/ijerph182111711.
4
Coronavirus Disease 2019 Case Surveillance - United States, January 22-May 30, 2020.2019 年冠状病毒病病例监测-美国,2020 年 1 月 22 日-5 月 30 日。
MMWR Morb Mortal Wkly Rep. 2020 Jun 19;69(24):759-765. doi: 10.15585/mmwr.mm6924e2.
5
Hypertension and COVID-19.高血压与2019冠状病毒病
Am J Hypertens. 2020 Apr 29;33(5):373-374. doi: 10.1093/ajh/hpaa057.
6
Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?高血压和糖尿病患者感染新型冠状病毒肺炎(COVID-19)的风险会增加吗?
Lancet Respir Med. 2020 Apr;8(4):e21. doi: 10.1016/S2213-2600(20)30116-8. Epub 2020 Mar 11.
7
Deep learning improves prediction of drug-drug and drug-food interactions.深度学习提高药物-药物和药物-食物相互作用的预测能力。
Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4304-E4311. doi: 10.1073/pnas.1803294115. Epub 2018 Apr 16.
8
The Drug Repurposing Hub: a next-generation drug library and information resource.药物再利用中心:一个新一代药物库及信息资源。
Nat Med. 2017 Apr 7;23(4):405-408. doi: 10.1038/nm.4306.
9
Drug interaction studies: study design, data analysis, and implications for dosing and labeling.药物相互作用研究:研究设计、数据分析以及对给药和标签的影响。
Clin Pharmacol Ther. 2007 Feb;81(2):298-304. doi: 10.1038/sj.clpt.6100054.